Redeye believes Integrum has good prospects of continuing to deliver positive EBIT during its high sales growth phase for the coming years. We regard the company as fully funded and argue that despite the recent doubling in the share (now trading in line with peers), its strong long-term fundamentals and our estimated 48% sales CAGR until 2025e should attract further investor interest.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Integrum Q2 - Alive and kicking

© Modular Finance, source Nordic Press Releases